Kane Biotech (CVE:KNE) Reaches New 1-Year Low – What’s Next?

Shares of Kane Biotech Inc. (CVE:KNE) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.03 and last traded at C$0.03, with a volume of 100000 shares traded. The stock had previously closed at C$0.03.

Kane Biotech Price Performance

The company has a quick ratio of 0.39, a current ratio of 0.90 and a debt-to-equity ratio of -289.57. The company’s fifty day moving average is C$0.04 and its 200-day moving average is C$0.04. The company has a market cap of C$5.02 million, a PE ratio of -0.38 and a beta of 1.04.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.